Format

Send to

Choose Destination
Am J Trop Med Hyg. 2019 May;100(5):1058-1065. doi: 10.4269/ajtmh.18-0981.

Falsified and Substandard Drugs: Stopping the Pandemic.

Author information

1
Rady Children's Hospital, San Diego, California.
2
Fogarty International Center, National Institutes of Health, Bethesda, Maryland.
3
School of Medicine, University of California, San Diego, La Jolla, California.
4
Pfizer Pharmaceuticals, Pfizer Global Security, New York, New York.
5
Global Health Impact Programs, United States Pharmacopeial Convention, Rockville, Maryland.
6
Public Affairs, Program for Appropriate Technology in Health (PATH), Seattle, Washington.
7
Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Abstract

Falsified and substandard medicines are associated with tens of thousands of deaths, mainly in young children in poor countries. Poor-quality drugs exact an annual economic toll of up to US$200 billion and contribute to the increasing peril of antimicrobial resistance. The WHO has emerged recently as the global leader in the battle against poor-quality drugs, and pharmaceutical companies have increased their roles in assuring the integrity of drug supply chains. Despite advances in drug quality surveillance and detection technology, more efforts are urgently required in research, policy, and field monitoring to halt the pandemic of bad drugs. In addition to strengthening international and national pharmaceutical governance, in part by national implementation of the Model Law on Medicines and Crime, a quantifiable Sustainable Development Goal target and an international convention to insure drug quality and safety are urgent priorities.

PMID:
30860016
PMCID:
PMC6493938
[Available on 2020-05-01]
DOI:
10.4269/ajtmh.18-0981

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center